Immunohistochemical staining
PreclinicalBiologic
Immunohistochemical staining is one of 44 biologic programs targeting Colorectal Carcinoma. It is currently in Preclinical.
2
Indications
3
Total Trials
2
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Colorectal Carcinoma
#DrugCompanyPhaseTrials
1Verzenio
Eli LillyApproved
Tukysa
PfizerApproved
Stivarga
BayerApproved
Avastin
RochePhase 3
Glucophage
EMD SeronoApproved
Inlyta
PPrism Pharmaceuticals
Approved
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Eloxatin
TevaPhase 2
Tecentriq
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- SSohag University